| Company Name: |
Biolab Reagents |
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
|
| | Navicixizumab Basic information |
| Product Name: | Navicixizumab | | Synonyms: | Navicixizumab;Research Grade Navicixizumab (DHJ65303);Research Grade Navicixizumab;Navicixizumab (anti-DLL4) | | CAS: | 1638338-43-8 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Navicixizumab Structure]() |
| | Navicixizumab Chemical Properties |
| | Navicixizumab Usage And Synthesis |
| Uses | Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer[1][2][3]. | | in vivo | Navicixizumab (15 mg/kg, once a week for 4 weeks) inhibits colon xenograft tumor growth[3].
| | References | [1] Fu S, et al. Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J Clin Oncol. 2022 Aug 10;40(23):2568-2577. DOI:10.1200/JCO.21.01801
[2] Perez-Fidalgo JA, et al. NOTCH signalling in ovarian cancer angiogenesis. Ann Transl Med. 2020 Dec;8(24):1705. DOI:10.21037/atm-20-4497
[3] Wan-Ching Yen, et al. Abstract C164: Dual targeting of the DLL4 and VEGF pathways with a bispecific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency. Mol Cancer Ther (2015) 14 (12_Supplement_2): C164. |
| | Navicixizumab Preparation Products And Raw materials |
|